Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Recurrence × BCG Vaccine × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Urinary Bladder Neoplasms 20 Non-Muscle Invasive Bladder Neoplasms 11 Colorectal Neoplasms 3 Colonic Neoplasms 3 Neoplasms 2 Lung Neoplasms 2 Side Effect of Drug 1 Sarcoma 1 Recurrence 1 Rectal Neoplasms 1 Prostatic Neoplasms 1 Parkinson Disease 4, Autosomal Dominant Lewy Body 1 Ovarian Neoplasms 1 Osteosarcoma 1 Oligospermia 1 Neuroblastoma 1 Melanoma 1 Fibrosis 1 Carcinoma, Transitional Cell 1 Carcinoma, Ovarian Epithelial 1 Breast Neoplasms 1

Interventions

Cyclophosphamide 133 Dexamethasone 107 Rituximab 70 fludarabine 65 Lenalidomide 59 Cytarabine 59 Gemcitabine 54 fludarabine phosphate 49 Bortezomib 48 pembrolizumab 46 venetoclax 45 Etoposide 44 Paclitaxel 43 Carboplatin 42 Cisplatin 41 pomalidomide 39 Peripheral Blood Stem Cell Transplantation 38 Filgrastim 37 Radiotherapy 35 Bevacizumab 33 Melphalan 31 Busulfan 31 Calcium Dobesilate 29 carfilzomib 28 Cyclosporine 28 Methotrexate 27 Azacitidine 26 Nivolumab 25 Mycophenolic Acid 25 Temozolomide 24

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT05037279 2025-02-20

EVER

Verity Pharmaceuticals Inc.

Phase 3 Recruiting

Urinary Bladder Neoplasms, Recurrence

Data powered by HemOnc (CC BY 4.0) Colophon ⚡